Pooled proportion of VTE among women who did not receive antepartum prophylaxis, in randomized trials of pregnant patients with positive antiphospholipid antibodies and obstetrical complications
| Reference . | VTE . | Antepartum risk (aspirin or placebo) . | |
|---|---|---|---|
| % . | 95% CI . | ||
| Prior pregnancy loss | |||
| Silver et al72 | 0/22* | ||
| Kutteh et al36 | 0/25 | ||
| Laskin et al73 | 0/46 | ||
| Rai et al37 | 0/45 | ||
| Pattison et al38 | 0/40 | ||
| Farquharson et al39 | 0/47 | ||
| Goel et al74 | 0/39 | ||
| Laskin et al42 | 0/20 | ||
| Subtotal | 0/284 | 0 | 0-1.3 |
| Prior placenta-mediated pregnancy complications | |||
| Rodger et al43 | 0/10† | ||
| van Hoorn et al40 | 0/16 | ||
| Subtotal | 0/26 | 0 | 0-27.8 |
| Total | 0/310 | 0 | 0-1.2 |
| Reference . | VTE . | Antepartum risk (aspirin or placebo) . | |
|---|---|---|---|
| % . | 95% CI . | ||
| Prior pregnancy loss | |||
| Silver et al72 | 0/22* | ||
| Kutteh et al36 | 0/25 | ||
| Laskin et al73 | 0/46 | ||
| Rai et al37 | 0/45 | ||
| Pattison et al38 | 0/40 | ||
| Farquharson et al39 | 0/47 | ||
| Goel et al74 | 0/39 | ||
| Laskin et al42 | 0/20 | ||
| Subtotal | 0/284 | 0 | 0-1.3 |
| Prior placenta-mediated pregnancy complications | |||
| Rodger et al43 | 0/10† | ||
| van Hoorn et al40 | 0/16 | ||
| Subtotal | 0/26 | 0 | 0-27.8 |
| Total | 0/310 | 0 | 0-1.2 |
Placenta-mediated pregnancy complications include pre-eclampsia, placental abruption, small-for-gestational-age neonate, and late pregnancy loss. The postpartum VTE risk was not reported in any of the included studies.
Included 1 patient with a prior history of VTE.
One patient with APS and prior provoked VTE had an antepartum VTE at 11 weeks of gestation while receiving LMWH prophylaxis (LMWH data not shown).